Daily, digital coverage of the latest PF (Pulmonary Fibrosis) news and perspectives.
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote on the importance of mental health, especially as the world begins to emerge from the COVID-19 pandemic. Charlene recently reflected on where she was one year ago at this time; when she had just begun to seriously consider a mental health leave from her career. While things are better for her now, she's seeing the impact of the pandemic on people's mental health every day and she wants to remind everyone that it's important to prioritize your mental health now more than ever. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Being on supplemental oxygen doesn't mean you have to avoid the hot summer months entirely. Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall shares some useful tips about this subject. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: http://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing the review request for Tyvaso DPI to be used in patients with pulmonary arterial hypertension (PH) and PH associated with interstitial lung diseases (ILDs), including those with IPF. Tyvaso is currently approved by the Food and Drug Administration in the US, however, the examination of how an inhaled form of Tyvaso (Tyvaso DPI) might better assist patients with PH and PH-ILDs is currently under way by United Therapeutics. If you have ILD-induced pulmonary hypertension, have you ever spoken to your doctor about Tyvaso? Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote trying to better understand the relationship between asthma and IPF. Prior to being told she also had asthma, Charlene thought it was uncommon for the two to be diagnosed together. Surprisingly, even if an IPF patient doesn't have asthma, many use inhaled therapies such as Ventolin, to alleviate their lung disease symptoms. As a patient living with IPF/PF: have you ever discussed asthma or asthmatic symptoms with your doctor? If so, what was done to alleviate them? Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing a study looking at self-reactive antibodies and the effectiveness of Esbriet. Many times, patients with IPF have an underlying autoimmune disease which may alter the effectiveness of one of the anti-fibrotic medications used to manage IPF. This study conducted in South Korea over five years suggests that if an IPF patient doesn't respond to Esbriet, they should be re-evaluated for an underlying autoimmune disease. As a patient living with IPF/PF: have you been diagnosed with an underlying autoimmune disease? Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote following a week of trying to manage new medications that weren't helpful. Charlene felt frustrated and discouraged when her prescribed therapies weren't relieving a sudden increase in shortness of breath and writes about where to turn when new medications aren't effective. Topping that list is connecting with other patients, which Charlene finds powerful and comforting; there is no greater source of information than from fellow rare disease patients. As a patient living with IPF/PF: where do you turn when a newly prescribed medication isn't helpful? Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing the events planned for 2021 Rare Disease Week on Capitol Hill. Amid roundtable discussions, policy updates and documentary screenings, patients and advocates will have an opportunity to win grants through the EveryLife Foundation for a rare disease organization of their choosing. Check out all the action for this year's Rare Disease Week on Capitol Hill on the EveryLife Foundations' homepage. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote on the importance of emergency preparedness plans and communication. Living with a life-threatening illness like IPF means emergencies can arise unexpectedly, but they can be a little less daunting if you do some work ahead of time in anticipation of them. Read more on how you can prepare for an emergency and why communication is key! Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article on the effectiveness of AP01 (inhaled pirfenidone) following an Australian study on IPF patients. Both the safety profile and side effects are promising, along with the hope from the pharmaceutical company that more of the drug will get into the lungs via an aerosol consumption method. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote on the power of sharing your IPF story and how stories, in general, can be a foundation for change. Charlene is desperate to debunk the myth that young adults aren't diagnosed with IPF, and she's calling on fellow patients who fall in that age group to be vulnerable and share your story. It is our lived experience (and stories) that can be a catalyst for conversation and spark change for those living with this cruel lung disease. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads the first piece from new columnist Ann Reynoso, where she shares her experience of being diagnosed with lymphocytic interstitial pneumonia (LIP). As Ann describes, there are a vast number of lung diseases and sometimes, getting an accurate diagnosis is difficult. Listen Ann’s experience of noticing symptoms and how she managed to get her diagnosis of LIP and is now learning to live with it. Welcome to the PF columnist team, Ann!Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing a collaboration between Vicore Pharma and Alex Therapeutics, focusing on the mental health of patients living with IPF. The newly designed app will allow patients to access artificial intelligence that can support their mental health needs, such as anxiety and depression, through the use of cognitive behavioural therapy (CBT). Having access to this resource at a patient’s fingertips could be transformative in helping them cope with their disease.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a piece by co-columnist Christie Patient, as she reflects on the importance of sharing stories as survivors of IPF and lung transplantation. Christie continues to share her Mom’s lung transplant experience despite the raw emotions associated with her being so sick and encourages others to do the same because it helps those currently in the fight with this terrible disease.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote on some of the luxuries that IPF has stolen from her since being diagnosed five years ago. Charlene regularly tries to embrace the positives, but sometimes, being open and honest about the frustrations of this disease is therapeutic for her and getting them down on paper helps too. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column summarizing the findings from two leading healthcare centers, John Hopkins University and Mayo Clinic, on the effectiveness of the mRNA vaccinations for transplant recipients. After one dose of the Pfizer or Moderna vaccines, researchers found the effectiveness to be significantly less in transplant recipients who are immunosuppressed compared to those who aren’t. However, more hope was provided after they studied the second dose as transplant patients were increasingly protected, albeit still less than those of their healthy counterparts.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote on exposing unexpected sources of mold in the home and how to eliminate them. Charlene was surprised to find where mold might exist in her home and is now actively taking the steps to remove such a risk to her lungs; something that is detrimental to the overall health of a patient with a pulmonary disease.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article examining the efficacy of Ofev among elderly patients living with IPF, who also had comorbidities. The 2021 study ultimately determined the benefits of Ofev were similar in elderly IPF patients and among those who had few or several comorbidities. However, patients who were older were more likely to discontinue use of Ofev due to adverse side effects such as diarrhea.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column summarizing a study examining the effectiveness of chemotherapy on patients with IPF. Both patients in the study had IPF and were put on a chemotherapy regimen to treat small-cell lung cancer (SCLC). The study determined that the chemotherapy these patients needed were effective against the SCLC without causing progression in their IPF. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote on the phenomenon known to the rare disease community as ‘scanxiety’. While Charlene still experiences this herself prior to test results, scans or bloodwork as a patient with IPF; she has some tips on managing generalized anxiety that can help rare disease patients who are struggling with scanxiety.
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a piece from co-columnist Emma Schmitz on weighing out the risks of her Mom visiting her grandkids as a lung transplant patient, now vaccinated, vs. the reward. Emma is looking forward to her parents visit now that they are both vaccinated and some parts of the world start to gain traction against COVID-19. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a summary of a case report on the use of Ofev in the treatment for non-small cell lung cancer. Unexpectedly, the use of Ofev on a patient with this type of cancer and IPF, showed an antitumor effect and a stabilization of lung function, the report showed. Other reports have yielded similar results, indicating that Ofev may be an effective therapy in helping treat both IPF and non-small cell lung cancer.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an column she wrote summarizing what constitutes a bad clinic day for her. Delayed appointments, excessive needles or scans to monitor disease progression, and poor test results are just a few things that make clinic days difficult for Charlene.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing a study with real-world data on the safety and effectiveness of Ofev and Esbriet for IPF patients. The study ultimately revealed that these antifibrotics are having a promising effect on progression-free survival, lung function and mortality among IPF patients. It also revealed that Ofev seems to be better tolerated in the early stages of therapy with the antifibrotics medications.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote on COVID-19 and how precautions to protect ourselves from the virus, illuminates some of the habits rare disease patients face. In particular, Charlene discusses how people have now adapted to wearing a mask, obsessively washing their hands and cancelling social plans if they are ill; all of which are precautions patients with IPF have been taking for years. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing a study of real-world data from a registry of IPF patients in the UK. Ultimately, the study determined that changes in diagnosing and managing patients with IPF in the UK were occurring for the better, based on a review of the registry patients between 2013-2019. Vital improvements in patient care were particularly noted, and researchers indicated it is important to consider these improvements for the development of healthcare policies, impacting longer term outcomes.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing a study examining fine particulate air pollutants and acute exacerbations or flare-ups of IPF. The study looked to understand the risk factor associated with such pollutants and found that exposure to nitric oxide and PM2.5, a type of fine particular air pollutant does increase the risk of an acute exacerbation among IPF patients.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote about her experience being vaccinated and wrongly thinking she could start giving hugs again. In particular, Charlene is longing to hug her nephews but now knows it’ll be a little longer until everyone is vaccinated and it’s safe to do that. She writes about how she’s angry at the pandemic from stealing her already-limited time with loved ones due to her diagnosis of idiopathic pulmonary fibrosis (IPF). This is true even for patients who are post lung transplantation.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote about her experience, or lack thereof, with clinical trials as a young adult. She’s always excluded from participating simply due to her age, despite the importance of better understanding this disease in young people. Charlene wishes she could share what her experience with clinical trials have been when others ask, but unfortunately, she doesn’t have any to share.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing recommendations from a data safety and monitoring board regarding the dose of treatment in the Galactic-1 trial GB0139. Once these recommendations are implemented, the study will continue to find an inhaled therapy effective in the fight against IPF, especially for those who are not taking Ofev or Esbriet.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article from co-columnist Christie Patient about getting her COVID-19 vaccine early as a caregiver. Christie shares her guilt for being eligible to receive the vaccine ahead of others at higher risk, but then recounts the importance of everyone getting vaccinated to build herd immunity faster.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing a meta-analysis of patient-control studies to examine the increased risk of IPF from occupational and environmental exposures. It was found that exposure to pesticides, metal dust and wood dust increases the risk of IPF along with an occupational history of farming or agriculture or among those who ever smoked.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote summarizing the virtual Rare Disease Day event BioNews recently offered. On top of a successful event, patients highlighted the importance of offering an event like this where rare disease patients are given the opportunity to come together, regardless of which disease they had. Charlene reflects on all the commonalities that exist among rare disease patients following that event.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article highlighting a new device being used at Duke University Hospital to help improve the successful transportation of donor lungs to recipients awaiting lung transplantation. LUNGguard is a device of Paragnox Technologies and is being used to cold store lungs to extend time between harvest from a donor to transplantation, subsequently resulting in more lungs being available to patients.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article from co-columnist Emma Schmitz on how she misses giving her Mom hugs amid the current COVID-19 pandemic. Not only is this discouraged from a public health guideline, Emma strives to be extra cautious as her Mom recovers from a lung transplant and is considered immune-suppressed. Read how something as simple as a hug is missed amid our current global health crisis.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing the results of a Eurodis Survey highlighting the healthcare experience for patients with a rare disease. Respondents to the survey identified three priority healthcare areas where changes could be made to help better care for patients with rare or complex diseases. Eurodis hopes the results of this survey will inspire policymakers to improve care to patients with a rare disease in Europe.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote on helping others manage stress amid the COVID-19 pandemic. Everyone deals with stress differently, but collectively, this pandemic has forced us to utilize many different coping skills to manage the stress of our current health crisis. Read some tips on how to help others effectively manage pandemic-related stress.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing the development of a lung-on-a-chip which will provide a more precise model for studying lung disorders, such as PF. Researchers at the University of Bern in Switzerland hope the application of this technology will advance both basic research into lung diseases and improve personalized medicine.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a piece from fellow columnist Christie Patient on the hope she feels after her parents both received their first COVID-19 vaccination. Christie’s Mom, Holly, is a lung transplant recipient and thus, Christie and her family have understandably been fearful of the virus throughout the last year. While we have a way to go before things are considered “normal” again, Christie feels hopeful as a result of the vaccine.Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article announcing a priority review by the FDA on using Esbriet as a treatment for Unclassifiable Interstitial Lung Diseases (UILDs). Currently, there are no treatment options to slow the fibrotic progression for patients living with a UILD so the priority review, pending it’s results, could bring hope for people who otherwise have no option to treat their UILD. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote on the importance of goal-setting as a contributor to better overall health. Charlene has found this particularly important as she continues to recover and starts a new job. She also shares some of the tips that help her achieve those goals. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article highlighting an upcoming event by the European IPF and Related Disorders Federation (EU-IPFF). This virtual summit was created for patients, by patients and will focus on the patient voice and experience. To learn more about this virtual event, visit: eu-ipff.org Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote in memory of Don Prager, known to the PF community at Donnie Vapor. Charlene shares memories of Donnie in this piece, along with what she and other members of the PF community will miss most about him. Charlene is still contemplating how else to honor this great man but invites others to share their memories of him after reading this piece. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing a recent webinar where key staff from NORD, the FDA and the CDC addressed concerns regarding the COVID-19 vaccines from the rare disease community. Among many other messages, an important takeaway from this webinar is that the current COVID-19 vaccines are safe for the rare disease community, including those living with pulmonary fibrosis. The full webinar discussion can be found on NORD’s homepage. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article from co-columnist Emma Schmitz who chronicled her Mom’s lung transplant experience amid COVID-19. Emma’s Mom received a single lung transplant in May of last year, and despite having to stay out of the hospital due to the pandemic, Emma shares what the experience was like for her. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing a study out of Kindai University in Japan, where researchers investigated outcomes of IPF patients who experienced a pneumothorax (collapsed lung). They concluded that unfortunately, a pneumothorax among IPF patients can be difficult to treat and is associated with poorer outcomes, and noted that recurrence is common, especially among patients requiring a chest tube drainage for their first pneumothorax. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she recently wrote on her experience with post-traumatic stress disorder (PTSD). Charlene decided it was important to be vulnerable and discuss this topic, as she believes PTSD might be more common among chronically ill patients than we think, including those living with IPF. Charlene shares both her struggle with the disorder and what helps her combat it. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a summary of a study investigating fatigue in IPF patients (as measured by a Fatigue Assessment Scale, FAS) in those taking both Esbriet and Ofev. Unsurprisingly, the study revealed that fatigue is IPF patients suffer substantially from fatigue, regardless of the type of anti-fibrotic therapy they are taking. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads a column she wrote to help the chronic illness community address any pandemic-related anxiety through various resources. Many patients living with IPF are not immune to feeling anxious, and the current global health crisis has unfortunately increased those feelings. If you’re struggling and needing help, please check out the resources listed in this briefing. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing a National Institute of Health (NIH) grant awarded to Boston University School of Medicine to create a cell model of IPF. This will help investigators better understand the processes that initiate and drive the progression of this cruel lung disease. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing a European study examining the health-related quality of life (HRQoL) of patients living with idiopathic pulmonary fibrosis. Unsurprisingly, disease severity and age consistently emerged as two causes of decreased HRQoL among patients. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing an initiative between IPF patient, Nick Brown and the Three Lakes Foundation (TLF). This partnership is to help raise awareness for IPF while detailing the efforts of TLF along with sharing Nick’s story of being diagnosed with IPF as a young adult and subsequently receiving his double lung transplant. Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com
© 2020-2025 Ivy Podcast Discovery LLC
